China Business Daily (Reporter Ma Jia text/photo)在全球醫療健康產業加速變革的背景下，中國市場的戰略地位日益凸顯。3月28日，在2025中關村論壇年會——監管科學與生物醫藥高品質發展論壇上，艾昆緯（IQVIA）亞太區總裁宓子厚在接受中國商報記者採訪時多次強調對中國市場的長期信心，並表示，在全球新藥早期研發管線中，中國貢獻佔比不斷提升，正在逐步縮小與歐美的差距。

Mi Zihou, President of IQVIA Asia Pacific.

As the world's leading provider of clinical research services, business insights and healthcare intelligence solutions, IQVIA has been deeply involved in the Chinese market for 30 years and is the first international CRO (Pharmaceutical R&D Outsourcing Service Agency) company to enter China.

Mi Zihou said: "We are firmly optimistic about the Chinese market and are willing to invest funds and resources in the Chinese market. ”

According to Mi Zihou, IQVIA has been cooperating with emerging biotech companies in China for a long time. IQVIA will help from the design of the product clinical protocol, patient recruitment to data management and analysis, including the clinical trial of the product overseas. For example, IQVIA collaborates with local pharmaceutical companies in the field of real-world research (RWE) to help local pharmaceutical companies optimize their medical insurance strategies and post-marketing studies. For example, by analyzing data on patients with rare diseases, we can evaluate the economic impact of medical insurance inclusion and provide a scientific basis for social policy making.

According to IQVIA data, in 30 years, 0% of the clinical trial programs launched worldwide came from the United States, 0% from China, and 0% from Europe. In about 0 years, 0% of the world's new drug R&D pipeline came from the United States, 0% from Europe, and China only contributed about 0%. The share of Chinese companies in the number of clinical trial launches in the world has risen significantly, from 0% to 0% in the last 0 years.

"The Chinese market has steadily become the center of global innovation. In hot areas such as oncology and immunotherapy, Chinese pharmaceutical companies have even become important players in global innovation, and we are very optimistic about the Chinese market. In the Chinese market, we are also working with government departments to set up investment funds to get more involved in China's innovation ecosystem. ”

In addition, Mi Zihou proposed that the digital and intelligent transformation of China's clinical research has entered the "fast lane". AI technology is reshaping the entire clinical trial process – from protocol design, patient recruitment to data management and analysis, the application of AI can reduce labor costs by 30% and shorten the R&D cycle by 0%.

[Source: China Business Daily]